Solventum raised its 2026 EPS outlook to $7.20 to $7.30, reported normalized organic growth of approximately 4%, expects full-year gross margin of approximately 57%, and says separation from 3M is more than 90% complete.
SOLV · Solventum Corp
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Price & Indicators
Up next
Latest documents
Solventum reported third-quarter sales of $1,949 million, down 7.0%, and operating income of $68 million, down 96.0%, as the prior-year divestiture gain fell away and ERP order timing weighed on sales.
Solventum reported third-quarter sales of $1.9 billion, down 7.0%, and adjusted diluted EPS of $1.45, while raising full-year adjusted EPS guidance to $7.20 to $7.30 and expecting organic sales growth toward the high end of +2.5% to +3.0%.
Metrics snapshot
Useful current figures from the complete screener profile.
Quarterly results
* Q4 derived as the full year minus Q1 to Q3.
AI Brief
Q3 FY26 earnings call · Nov 5, 2026TL;DR. Solventum raised adjusted EPS guidance, moved organic sales and operating-margin guidance toward the high ends of their ranges, expanded gross margin and achieved approximately 4% normalized organic growth, and reported growth from Acera and favorable regulatory clearance. It also nearly completed the 3M separation, generated $97 million of quarterly free cash flow, maintained $200 to $300 million free-cash-flow guidance, and benefited from a renegotiated 3M supply agreement. Third-quarter reported and organic sales, adjusted operating margin and adjusted EPS declined, while the planned HIS separation is expected to dilute annualized net operating margin by approximately 400 basis points.
- + Full-year adjusted EPS guidance increased to $7.20 to $7.30 from $7.10 to $7.20.
- + Full-year organic sales growth guidance moved toward the high end of 2.5% to 3.0%.
- + Full-year operating-margin guidance moved toward the high end of 22.2% to 22.7%, while full-year gross margin is expected to be approximately 57%.
- − Third-quarter reported sales declined 7.0% and organic sales declined 2.8%.
- − Adjusted operating margin declined 70 basis points year over year to 19.9%.
- − Adjusted diluted earnings per share declined 3.6% to $1.45.
- − The ERP-related advance-order reversal reduced organic sales growth by 630 basis points in the quarter.
- − The planned HIS separation is expected to dilute annualized net operating margin by approximately 400 basis points.
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Still-open targets the latest release did not restate under the same label.
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Strong BuyIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Adjusted operating income margin non-GAAP | 24.2% | Six months ended June 30, 2026 | — |
| Free cash flow non-GAAP | -$129M | Six months ended June 30, 2026 | — |
GAAP → non-GAAP reconciliationGAAP Net cash provided by operating activities 227M
-83M Purchases of property, plant and equipment
= Free cash flow 144M
|
|||
| Organic sales growth non-GAAP | 5.8% | Six months ended June 30, 2026 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Medical Instruments & Supplies — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
SOLV
this stock
Solventum Corp
|
$15.05B | +11.9% | +0.9% | 98.5 | 3.0% |
|
ISRG
Intuitive Surgical Inc
|
$150.74B | -22.7% | +20.5% | 53.1 | 2.0% |
|
BDX
Becton Dickinson & Co
|
$58.96B | — | +8.2% | 95.8 | 3.0% |
|
MDLN
Medline Inc.
|
$51.52B | -6.7% | +11.5% | — | 2.9% |
|
ALC
Alcon Inc
|
$35.38B | -6.6% | +10.5% | — | 3.8% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every section- Filed
- Nov 5, 2026
- This year
- 18
Solventum reported third-quarter sales of $1,949 million, down 7.0%, and operating income of $68 million, down 96.0%, as the prior-year divestiture gain fell away and ERP order timing weighed on sales.
ViewPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| SOLV | -2.0% | +4.2% | +16.8% | +9.0% | +11.9% |
| SPY | -1.7% | -3.5% | -1.4% | -2.1% | +8.5% |
| vs SPY | -0.3% | +7.7% | +18.2% | +11.1% | +3.4% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.